Translate 
Abstract
The annual Clinical Trials in Alzheimer’s Disease (CTAD) Congress brings together global experts to discuss developments in Alzheimer’s disease (AD) clinical research and showcase researchers’ work on AD trials. This article describes a recently initiated Phase II trial of a novel anti-tau monoclonal antibody, BMS-986446, the design for which was presented at the 17th CTAD Congress in Madrid, Spain, on 31st October 2024. BMS-986446 targets the microtubule binding region of the tau molecule to inhibit interneural transmission and prevent pathogenic spread of tau aggregates. The TargetTau-1 study (NCT06268886) will assess the efficacy of BMS-986446 by evaluating clinical, cognitive and functional decline, and tau deposition, and investigate the safety and tolerability profile of BMS-986446 in approximately 475 patients with early AD.
Published Version
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
